title: A randomized phase II study of a new tick-borne encephalitis vaccine using three different doses and two immunization regimens.
abstract: A new, highly purified inactivated tick-borne encephalitis (TBE) vaccine (FSME-Vaccine Behring, BI 71.061) was recently registered in Germany. A multinational phase II study was performed in seven centres located in areas endemic for TBE. A total of 379 healthy adults were randomly allocated into three dosage groups (1.0, 1.5 and 2.0 micrograms antigen per dose, respectively) and into two immunization schedules [vaccination with one dose of 0.5 ml intramuscularly on days 0, 7 and 21 (abbreviated schedule), or on days 0, 28 and 300 (conventional schedule)]. Antibody response to vaccination was assayed by enzyme-linked immunosorbent assay (ELISA), haemagglutination inhibition test (HIT) and neutralization test (NT). Seroconversion rates in the different groups 28 days after one single dose were 75.3-83.5% in ELISA, 35.8-50.6% in HIT, and 100% in NT. All vaccinees showed seroconversion in all tests on day 42 in the conventional schedule and on day 35 in the abbreviated schedule, with the exception of one subject, who remained seronegative in HIT only. Geometric mean titres (GMT) of about 3000 in ELISA were achieved by two vaccinations in the conventional schedule and showed a booster increase to 5500-8000 GMT after revaccination on day 300. Overall frequency of adverse events (related and unrelated) was 37% (conventional schedule) and 46% (abbreviated schedule) after the first, 9% and 21% after the second, and 5% and 15% after the third vaccination, respectively. Generally, side effects were mild and transient, including mainly headache, fever, malaise and local irritation. Serious, vaccine-related side effects did not occur.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Behringwerke AG, Marburg, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Harabacz
authors.forename: H
authors.initials: H
authors.lastname: Bock
authors.forename: C
authors.initials: C
authors.lastname: Jüngst
authors.forename: U
authors.initials: U
authors.lastname: Klockmann
authors.forename: M
authors.initials: M
authors.lastname: Praus
authors.forename: R
authors.initials: R
authors.lastname: Weber
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000096:biosynthesis; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004669:Encephalitis Viruses, Tick-Borne / Q000276:immunology*; D004675:Encephalitis, Tick-Borne / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011897:Random Allocation; D015164:Vaccines, Inactivated / Q000008:administration & dosage* / Q000009:adverse effects; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000914:Antibodies, Viral; D015164:Vaccines, Inactivated; D014765:Viral Vaccines